A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema

BACKGROUND: Patients with hereditary angioedema with C1 inhibitor deficiency or dysfunction have burdensome recurrent angioedema attacks. The safety, efficacy, and health‐related quality of life (HRQoL) outcomes of C1 inhibitor (C1‐INH) prophylaxis (intravenously administered) in patients aged 6‐11 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Aygören‐Pürsün, Emel, Soteres, Daniel F., Nieto‐Martinez, Sandra A., Christensen, Jim, Jacobson, Kraig W., Moldovan, Dumitru, Van Leerberghe, Arthur, Tang, Yongqiang, Lu, Peng, Vardi, Moshe, Schranz, Jennifer, Martinez‐Saguer, Inmaculada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851661/
https://www.ncbi.nlm.nih.gov/pubmed/30968444
http://dx.doi.org/10.1111/pai.13060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851661/
https://www.ncbi.nlm.nih.gov/pubmed/30968444
http://dx.doi.org/10.1111/pai.13060

Ejemplares similares